This study investigates the expression level of cathepsin D (CTSD) in the serum of patients with acute myeloid leukemia (AML) and its clinical significance and evaluates its potential value as a prognostic biomarker for AML. This evidence concerns the gene CTSD and acute myeloid leukemia.